Eli Lilly is one of the leading pharmaceutical companies in the world with a rich history – it has been operating for over a century.
The company was founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, USA.
At the time he was frustrated with the poorly prepared and ineffective medicines in the Midwest US, so he made a commitment to himself and society that he would create a pharmaceutical company with products of the highest possible quality.
Throughout its existence Eli Lily has played a role in the discovery and development of important medical breakthroughs.
In 1923, Lilly introduced the first commercially available insulin product (under the name Iletin). Decades later it had another major impact on the pharmaceutical industry by being the first company to mass-produce the antibiotic penicillin.
Eli Lilly has marketed and produced a range of well known drugs, including:
- Prozac® (for the treatment of clinical depression),
- Cialis® (for the treatment of erectile dysfunction),
- Symbyax® (the first FDA-approved medication to treat bipolar depression), and
- Cymbalta® (for the maintenance of major depressive disorder).
Eli Lilly – Business Focus
Lilly has five main business areas: Lilly Bio-Medicines, Lilly Diabetes, Elanco Animal Health, Lilly Oncology, and its Emerging Markets business.
Lilly Bio-Medicines: In terms of sales this is the largest of the five business areas. This area of the company focuses on making medicines in neuroscience, cardiovascular, urology, musculoskeletal and autoimmunity.
Lilly Diabetes – This area of the company focuses on the development of diabetes medications as well as Diabetes support programs.
Elanco Animal Health – Elanco focuses on the production and marketing of products for animal health.
Emerging Markets – This division focuses on providing services to emerging markets such as China, Korea, Turkey, Russia, Brazil and Mexico.
Eli Lilly – Company Overview
- Chairman and CEO: John C. Lechleiter
- Company head office: Indianapolis, Indiana, United States
- Employees: 38,000 (as of December 31, 2013)
- Type: Public
- Traded as: NYSE: LLY
- S&P 500 Component
- Manufacturing plants in 15 countries
- R&D facilities in 8 countries
- Products are marketed in over 125 countries
Eli Lilly – Financial Results 2013
Consolidated Statement of Operations
Revenue: $23.1131 billion USD
Research and Development: $5.5313 billion USD
Net income: $4.6848 billion USD
Earnings per share – basic: $4.33 USD
Earnings per share – diluted: $4.32 USD
Consolidated Statement of Comprehensive Income
Comprehensive income: $6.4792 billion USD
Consolidated Balance Sheet
Total assets: $35.2487 billion USD
Total equity: $17.6407 billion USD
Read the full 2013 Eli Lilly financial results report.
Eli Lilly – Developments
John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer, commented on the 2013 financial results:
“Lilly’s fourth-quarter 2013 results reflect the initial impact from the U.S. patent expiration for Cymbalta. The loss of the Cymbalta patent, along with the expiration of the U.S. patent for Evista in March of this year will result in a substantial decline in revenue and earnings in 2014. Yet, far from seeing 2014 as a trough year for Lilly, we see it as a moment of tremendous opportunity. We anticipate launching several new medicines this year and returning our company to growth in 2015 and beyond.”